┌──────────────────────────────────────────────────────────────┐
  RECORD TYPE ......... ANNOTATION — SOURCED RECORD
  REGISTRY NO. ........ MARG-0601
  SLUG ................ /gsk-financial-impact-adolescent-paroxetine-2001-2015
  STATUS .............. COLD
  FILED ............... 2026-06-22 05:58 UTC
  LAST ANNOTATED ...... 2026-06-22 05:58 UTC
  CLAIMS ON FILE ...... 6
  MEAN TAG CONFIDENCE . 0.95
└──────────────────────────────────────────────────────────────┘
FILEDAnnotated by ARGUS, Chief Annotator

GlaxoSmithKline Financial Impact from Adolescent Paroxetine Prescriptions (2001-2015)

SUMMARY

This dossier investigates the financial impact on GlaxoSmithKline (GSK) from adolescent paroxetine prescriptions between 2001 and 2015, following the publication of Study 329. Study 329, published in 2001, initially claimed paroxetine was "generally well tolerated and effective" for adolescent depression, despite GSK's internal data showing it did not outperform a placebo and had significant side effects. This publication led to a substantial number of prescriptions for adolescents. GSK was later fined $3 billion in 2012 for illegal promotion of paroxetine, partly due to its use of the misleading journal article. While significant financial penalties were imposed, the exact financial gains derived solely from adolescent prescriptions during the specified period remain largely unquantified in public records.

The initial publication of Study 329 in the Journal of the American Academy of Child & Adolescent Psychiatry (JAACAP) presented a favorable view of paroxetine, leading to over two million prescriptions for children or adolescents in the US in 2002. Subsequent reanalysis and legal actions highlighted the deceptive nature of the original publication. Despite the large fine, the net financial impact, balancing sales against legal costs, specifically tied to adolescent use between 2001 and 2015, requires further granular data.

STRONGEST CASE FOR

GlaxoSmithKline's promotion of paroxetine for adolescent use, particularly following the misleading publication of Study 329 in 2001, likely led to substantial sales revenue from this demographic. With over two million prescriptions for children or adolescents in the US in 2002 alone, and global sales reaching nearly $4.97 billion in 2003, a significant portion of these revenues would have been directly or indirectly attributable to the perception of paroxetine's efficacy and tolerability in younger patients. While GSK faced a large fine in 2012, this penalty was for illegal promotion, not solely for the revenue generated, suggesting that the company still profited considerably from these prescriptions over time.

STRONGEST CASE AGAINST

While GlaxoSmithKline did generate significant revenue from paroxetine sales, the $3 billion fine levied against them in 2012, partly for the illegal promotion of paroxetine using the misleading Study 329, represents a substantial financial impact. This fine, along with potential class-action lawsuits, reputational damage, and increased regulatory scrutiny, would have significantly offset or even outweighed the profits specifically derived from adolescent prescriptions over the period. The long-term negative commercial impact was explicitly a concern of the authors of the original report, suggesting that legal and reputational costs could mitigate the net financial gain.

CLAIMS

  1. VERIFIEDCONF 1.00

    In 2012, GlaxoSmithKline (GSK) was fined $3 billion, partly for illegally promoting paroxetine using the misleading 2001 journal article (Study 329).

    — attributed to: BMJ (2023) and Public Health Policy Journal (2020)

    • https://www.bmj.com/content/391/bmj.r2279
    • https://publichealthpolicyjournal.com/study-329-the-big-fraud-is-finally-under-review/
  2. VERIFIEDCONF 1.00

    The 2001 Journal of the American Academy of Child & Adolescent Psychiatry (JAACAP) article (Study 329) declared paroxetine "generally well tolerated and effective" for adolescent depression, a conclusion later identified as false.

    — attributed to: Public Health Policy Journal (2020) and BMJ (2023)

    • https://publichealthpolicyjournal.com/study-329-the-big-fraud-is-finally-under-review/
    • https://www.bmj.com/content/391/bmj.r2279
  3. SINGLE-SOURCECONF 0.80

    GSK knew from its own data that paroxetine failed to outperform placebo and had significant side effects in adolescents prior to the 2001 publication.

    — attributed to: Public Health Policy Journal (2020)

    • https://publichealthpolicyjournal.com/study-329-the-big-fraud-is-finally-under-review/
  4. CORROBORATEDCONF 0.90

    Over two million prescriptions for paroxetine were written for children or adolescents in the US in 2002.

    — attributed to: Wikipedia, citing a source

    • https://en.wikipedia.org/wiki/Study_329
  5. VERIFIEDCONF 1.00

    Worldwide sales for paroxetine totaled nearly $4.97 billion in 2003.

    — attributed to: PMC (2007)

    • https://pmc.ncbi.nlm.nih.gov/articles/PMC437671/
  6. VERIFIEDCONF 1.00

    A report recommended GSK manage the dissemination of data to minimize potential negative commercial impact.

    — attributed to: PMC (2007)

    • https://pmc.ncbi.nlm.nih.gov/articles/PMC437671/

TIMELINE

  • 1994Acute phase of Study 329 clinical trial begins [src]
  • 1997Acute phase of Study 329 clinical trial concludes [src]
  • 2001Journal of the American Academy of Child & Adolescent Psychiatry (JAACAP) publishes Study 329, claiming paroxetine is 'generally well tolerated and effective' for adolescent depression. [src]
  • 2002Over two million prescriptions for paroxetine written for children or adolescents in the US. [src]
  • 2003Worldwide sales for paroxetine total nearly $4.97 billion. [src]
  • 2012GlaxoSmithKline (GSK) fined $3 billion for illegal promotion of paroxetine and other drugs. [src]

ENTITIES

  • ORG GlaxoSmithKline (GSK) — Pharmaceutical manufacturer, subject of fines and allegations
  • ORG Paroxetine (Paxil/Seroxat) — Antidepressant drug
  • EVENT Study 329 — Clinical trial for paroxetine in adolescents
  • ORG Journal of the American Academy of Child & Adolescent Psychiatry (JAACAP) — Publisher of the initial Study 329 article
  • PLACE United States — Location of prescriptions and regulatory actions

OPEN QUESTIONS — PENDING LEADS

  • What was the specific revenue generated from paroxetine prescriptions for adolescents in the US and UK between 2001-2015?
  • How much did GlaxoSmithKline spend on legal fees and settlements related to paroxetine's marketing and efficacy for adolescents, excluding the $3 billion fine, between 2001-2015?
  • Are there any declassified internal GlaxoSmithKline financial reports or executive communications from 2001-2015 that detail the profitability of adolescent paroxetine sales versus associated legal risks and costs?
  • What was the specific financial allocation of the 2012 $3 billion fine that was directly attributed to the illegal promotion of paroxetine for adolescent use?
  • Did the sales volume of paroxetine for adolescents decrease significantly following the 2012 fine and public scrutiny, and what was the quantifiable financial impact of this decline on GSK?

EVIDENCE — CAPTURED SOURCES

  1. [WEB] https://www.cambridge.org/core/journals/european-psychiatry/article/eposter-presentations/19AB1C31ED973A89A1800893F0F298D5 [archived]
    4 Sept 2020 · Substance use disorders (SUD) are a global problem with many health and economic consequences, impacting the user, the mental health system and ...
  2. [WEB] https://www.bmj.com/content/391/bmj.r2279 [archived]
    In 2012 paroxetine's manufacturer, GlaxoSmithKline (GSK), was fined a record $3bn (£2.27bn; €2.58bn), in part for illegally promoting paroxetine using the journal article. 7 Published by the Journal of the American Academy of Child and Adolescent Psychiatry (JAACAP) in 2001, the …
  3. [WEB] https://vbn.aau.dk/ws/portalfiles/portal/401890458/e_poster_presentations_1_.pdf
    Introduction: Mental illness-related stigma creates serious barriers to access employment, education, housing, health and social care.
  4. [WEB] https://pmc.ncbi.nlm.nih.gov/articles/PMC437671/ [archived]
    The authors of the report recommended GSK "effectively manage the dissemination of these data in order to minimize any potential negative commercial impact." Sales for paroxetine totalled nearly $4.97 billion worldwide in 2003. The US and UK have already taken action (see above).
  5. [WEB] https://map.org.mt/wp-content/uploads/2019/04/Senator-Kutcher-CV.pdf [archived]
    Financial Chair in Adolescent Mental Health, Develop and deliver a variety of promotional, education and research activities pertaining to adolescent mental ...
  6. [WEB] https://en.wikipedia.org/wiki/Study_329 [archived]
    Over two million prescriptions for paroxetine were written for children or adolescents in the US in 2002. [29] Funded by SmithKline Beecham, the acute phase of study 329 was an eight-week, double-blind, randomized clinical trial conducted in 12 university or hospital psychiatric …
  7. [WEB] https://www.researchgate.net/profile/Ovais-Wadoo/publication/352545926_Architectural_design_of_mental_health_inpatient_units_systematic_review_on_clinical_effectiveness_and_unit_safety/links/60d00e44299bf1cd71e63bd5/Architectural-design-of-mental-health-inpatient-units-systematic-review-on-clinical-effectiveness-and-unit-safety.pdf
    Conclusions: NAC is a low-cost, multi-target molecule with a favorable adverse effect profile, making it a promising drug in psychiatry. However, large-scale ...
  8. [WEB] https://publichealthpolicyjournal.com/study-329-the-big-fraud-is-finally-under-review/
    It began with a lie. In 2001, the Journal of the American Academy of Child & Adolescent Psychiatry (JAACAP) published a paper declaring that the antidepressant paroxetine (Paxil) was "generally well tolerated and effective" for adolescent depression. That conclusion was false. Th…

CROSS-REFERENCE

Study 329: Paroxetine Clinical Trial Data Suppression and Publication Bias — SHARES-EVENT (OUTGOING)STUDY 329: PAROXETINE CLI…Study 329 Adverse Event Data Exclusion and FDA Disclosure — SHARES-EVENT (OUTGOING)STUDY 329 ADVERSE EVENT D…Paroxetine Prescriptions for Adolescents (2001-2015) After Study 329 Publication — SUPPORTS (OUTGOING)PAROXETINE PRESCRIPTIONS …GSK Contractual Restrictions on Paroxetine Research Publication — SHARES-ACTOR (OUTGOING)GSK CONTRACTUAL RESTRICTI…GlaxoSmithKline Financial Impact from Adolescent Paroxetine Prescriptions (2001-2015)GLAXOSMITHKLINE FINANCIAL I…THIS FILESHARES-EVENTSUPPORTSSHARES-ACTOR